{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T21:29:08Z","timestamp":1773869348000,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T00:00:00Z","timestamp":1686009600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s00108-023-01524-y","type":"journal-article","created":{"date-parts":[[2023,6,6]],"date-time":"2023-06-06T19:32:08Z","timestamp":1686079928000},"page":"895-906","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prim\u00e4re Fettstoffwechselst\u00f6rungen \u2013 Stellenwert in aktuellen Dyslipid\u00e4mieleitlinien und therapeutische Innovationen","Primary disorders of lipid metabolism: their place in current dyslipidemia guidelines and treatment innovations"],"prefix":"10.1007","volume":"64","author":[{"given":"G.","family":"Klose","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Gouni-Berthold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"M\u00e4rz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,6]]},"reference":[{"issue":"1","key":"1524_CR1","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach\u00a0F, Baigent\u00a0C, Catapano\u00a0AL et\u00a0al (2020) 2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart\u00a0J 41(1):111\u2013188","journal-title":"Eur Heart J"},{"key":"1524_CR2","unstructured":"https:\/\/www.leitlinien.de\/themen\/khk\/pdf\/khk-5aufl-vers1-lang.pdf. Zugegriffen: 10.02.23"},{"issue":"34","key":"1524_CR3","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren\u00a0FLJ, Mach\u00a0F, Smulders\u00a0YM et\u00a0al (2021) 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart\u00a0J 42(34):3227\u20133337","journal-title":"Eur Heart J"},{"issue":"5","key":"1524_CR4","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00059-017-4578-x","volume":"42","author":"W M\u00e4rz","year":"2017","unstructured":"M\u00e4rz\u00a0W, Grammer\u00a0T, Delgado\u00a0D, Kleber\u00a0ME (2017) Angeborene St\u00f6rungen im Lipoproteinstoffwechsel. Herz 42(5):449\u2013458","journal-title":"Herz"},{"issue":"1","key":"1524_CR5","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S2213-8587(19)30264-5","volume":"8","author":"RA Hegele","year":"2020","unstructured":"Hegele\u00a0RA, Bor\u00e9n\u00a0J, Ginsberg\u00a0HN et\u00a0al (2020) Rare dyslipidaemias, from phenotype to genotype to management: a\u00a0European Atherosclerosis Society task force consensus statement. Lancet Diabetes Endocrinol 8(1):50\u201367","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1524_CR6","first-page":"523","volume":"111","author":"G Klose","year":"2014","unstructured":"Klose\u00a0G, Laufs\u00a0U, M\u00e4rz\u00a0W, Windler\u00a0E (2014) Familial hypercholesterolemia: developments in diagnosis and treatment. Dtsch Arztebl Int 111:523\u2013529","journal-title":"Dtsch Arztebl Int"},{"key":"1524_CR7","unstructured":"https:\/\/www.fhscore.eu\/de-de\/fh-score. Zugegriffen: 10.02.23"},{"issue":"22","key":"1524_CR8","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","volume":"67","author":"AV Khera","year":"2016","unstructured":"Khera\u00a0AV, Won\u00a0HH, Peloso\u00a0GM et\u00a0al (2016) Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia. J\u00a0Am Coll Cardiol 67(22):2578\u20132589","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"1524_CR9","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamacardio.2019.5954","volume":"5","author":"M Trinder","year":"2020","unstructured":"Trinder\u00a0M, Francis\u00a0GA, Brunham\u00a0LR (2020) Association of monogenic vs polygenic hypercholesterolemia with risk of atherosclerotic cardiovascular disease. JAMA Cardiol 5(4):390\u2013399","journal-title":"JAMA Cardiol"},{"issue":"2","key":"1524_CR10","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000664","volume":"31","author":"L D\u2019Erasmo","year":"2020","unstructured":"D\u2019Erasmo\u00a0L, Di Costanzo\u00a0A, Arca\u00a0M (2020) Autosomal recessive hypercholesterolemia: update for 2020. Curr Opin Lipidol 31(2):56\u201361","journal-title":"Curr Opin Lipidol"},{"issue":"33","key":"1524_CR11","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","volume":"40","author":"A Langsted","year":"2019","unstructured":"Langsted\u00a0A, Kamstrup\u00a0PR, Nordestgaard\u00a0BG (2019) High lipoprotein(a) and high risk of mortality. Eur Heart\u00a0J 40(33):2760\u20132770","journal-title":"Eur Heart J"},{"issue":"1","key":"1524_CR12","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.jacl.2016.10.001","volume":"11","author":"C Koopal","year":"2017","unstructured":"Koopal\u00a0C, Marais\u00a0AD, Westerink\u00a0J, Visseren\u00a0FL (2017) Autosomal dominant familial dysbetalipoproteinemia: a pathophysiological framework and practical approach to diagnosis and therapy. J\u00a0Clin Lipidol 11(1):12\u201323","journal-title":"J Clin Lipidol"},{"issue":"1","key":"1524_CR13","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1210\/clinem\/dgac503","volume":"108","author":"M Paquette","year":"2022","unstructured":"Paquette\u00a0M, Bernard\u00a0S, Baass\u00a0A (2022) Dysbetalipoproteinemia is associated with increased risk of coronary and peripheral vascular disease. J\u00a0Clin Endocrinol Metab 108(1):184\u2013190","journal-title":"J Clin Endocrinol Metab"},{"issue":"47","key":"1524_CR14","doi-asserted-by":"crossref","first-page":"4791","DOI":"10.1093\/eurheartj\/ehab551","volume":"42","author":"HN Ginsberg","year":"2021","unstructured":"Ginsberg\u00a0HN, Packard\u00a0CJ, Chapman\u00a0MJ, Bor\u00e9n\u00a0J et al (2021) Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies\u2014a consensus statement from the European Atherosclerosis Society. Eur Heart\u00a0J 42(47):4791\u20134806","journal-title":"Eur Heart J"},{"issue":"4","key":"1524_CR15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/joim.13016","volume":"287","author":"A Baass","year":"2020","unstructured":"Baass\u00a0A, Paquette\u00a0M, Bernard\u00a0S, Hegele\u00a0RA (2020) Familial chylomicronemia syndrome: an under-recognized cause of severe hypertriglyceridaemia. J\u00a0Intern Med 287(4):340\u2013348","journal-title":"J Intern Med"},{"key":"1524_CR16","unstructured":"https:\/\/sobi-deutschland.de\/sites\/default\/files\/Fachinformation_Waylivra_Mai_2021.pdf. Zugegriffen: 10.02.23"},{"key":"1524_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2021.01.003","volume":"320","author":"AJ Vallejo-Vaz","year":"2021","unstructured":"Vallejo-Vaz\u00a0AJ, Packard\u00a0CJ, Ference\u00a0BA et al (2021) LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a\u00a0familial hypercholesterolemia phenotype: analysis from the secondary prevention 4S trial. Atherosclerosis 320:1\u20139","journal-title":"Atherosclerosis"},{"issue":"9965","key":"1524_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(14)61399-4","volume":"385","author":"FJ Raal","year":"2015","unstructured":"RUTHERFORD\u20112 Investigators, Raal\u00a0FJ, Stein\u00a0EA, Dufour\u00a0R et al (2015) PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a\u00a0randomised, double-blind, placebo-controlled trial. Lancet 385(9965):331\u2013340","journal-title":"Lancet"},{"key":"1524_CR19","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.atherosclerosis.2018.08.036","volume":"278","author":"M Farnier","year":"2018","unstructured":"Farnier\u00a0M, Kees Hovingh\u00a0G et al (2018) Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: an open-label extension of the ODYSSEY program. Atherosclerosis 278:307\u2013314","journal-title":"Atherosclerosis"},{"issue":"16","key":"1524_CR20","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1056\/NEJMoa1913805","volume":"382","author":"FJ Raal","year":"2020","unstructured":"ORION\u20119 Investigators, Raal\u00a0FJ, Kallend\u00a0D, Ray\u00a0KK et al (2020) Inclisiran for the treatment of Heterozygous familial hypercholesterolemia. N\u00a0Engl J Med 382(16):1520\u20131530","journal-title":"N Engl J Med"},{"key":"1524_CR21","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.atherosclerosis.2020.07.028","volume":"310","author":"S Aljenedil","year":"2020","unstructured":"Aljenedil\u00a0S, Alothman\u00a0L, B\u00e9langer\u00a0AM et\u00a0al (2020) Lomitapide for treatment of homozygous familial hypercholesterolemia: the Qu\u00e9bec experience. Atherosclerosis 310:54\u201363","journal-title":"Atherosclerosis"},{"key":"1524_CR22","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosissup.2019.08.037","volume":"40","author":"R Klingel","year":"2019","unstructured":"Klingel\u00a0R, Heigl\u00a0F, Schettler\u00a0V et\u00a0al (2019) Lipoprotein(a)\u2014Marker for cardiovascular risk and target for lipoprotein apheresis. Atheroscler Suppl 40:17\u201322","journal-title":"Atheroscler Suppl"},{"key":"1524_CR23","unstructured":"https:\/\/www.dgfn.eu\/apherese-standard.html. Zugegriffen: 10.02.23"},{"issue":"49","key":"1524_CR24","first-page":"825","volume":"116","author":"KG Parhofer","year":"2019","unstructured":"Parhofer\u00a0KG, Laufs\u00a0U (2019) The diagnosis and treatment of hypertriglyceridemia. Dtsch Arztebl Int 116(49):825\u2013832","journal-title":"Dtsch Arztebl Int"},{"issue":"1","key":"1524_CR25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1812792","volume":"380","author":"DL Bhatt","year":"2019","unstructured":"REDUCE-IT Investigators, Bhatt\u00a0DL, Steg\u00a0PG, Miller\u00a0M et al (2019) Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N\u00a0Engl J Med 380(1):11\u201322","journal-title":"N Engl J Med"},{"key":"1524_CR26","doi-asserted-by":"publisher","unstructured":"Waldmann E, Wu L, Busygina K, Altenhofer J et\u00a0al (2022) Effect of PCSK9 inhibition with evolocumab on lipoprotein subfractions in familial dysbetalipoproteinemia (type III hyperlipidemia). PLoS ONE 17(3). https:\/\/doi.org\/10.1371\/journal.pone.0265838","DOI":"10.1371\/journal.pone.0265838"},{"issue":"6","key":"1524_CR27","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1056\/NEJMoa1715944","volume":"381","author":"JL Witztum","year":"2019","unstructured":"Witztum\u00a0JL, Gaudet\u00a0D, Freedman\u00a0SD et\u00a0al (2019) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome. N\u00a0Engl J Med 381(6):531\u2013542","journal-title":"N Engl J Med"},{"key":"1524_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2023.03.007","author":"J Witztum","year":"2023","unstructured":"Witztum\u00a0J, Gaudet\u00a0D, Arca\u00a0M, Jones\u00a0A et al (2023) Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial. J\u00a0Clin Lipidol. https:\/\/doi.org\/10.1016\/j.jacl.2023.03.007","journal-title":"J Clin Lipidol"},{"issue":"5","key":"1524_CR29","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S2213-8587(21)00046-2","volume":"9","author":"I Gouni-Berthold","year":"2021","unstructured":"Gouni-Berthold\u00a0I, Alexander\u00a0VJ, Yang\u00a0Q et al (2021) Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a\u00a0multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol 9(5):264\u2013275","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1524_CR30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.atherosclerosis.2021.03.039","volume":"325","author":"M Averna","year":"2021","unstructured":"Averna\u00a0M, Banach\u00a0M, Bruckert\u00a0E, Drexel\u00a0H et al (2021) Practical guidance for combination lipid-modifying therapy in high- and very-high-risk patients: A statement from a\u00a0European Atherosclerosis Society Task Force. Atherosclerosis 325:99\u2013109","journal-title":"Atherosclerosis"},{"issue":"15","key":"1524_CR31","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1161\/CIRCULATIONAHA.122.061620","volume":"146","author":"ML O\u2019Donoghue","year":"2022","unstructured":"O\u2019Donoghue\u00a0ML, Giugliano\u00a0RP, Wiviott\u00a0SD, Atar\u00a0D et al (2022) Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation 146(15):1109\u20131119","journal-title":"Circulation"},{"key":"1524_CR32","doi-asserted-by":"crossref","first-page":"13457","DOI":"10.1038\/ncomms13457","volume":"7","author":"SL Pinkosky","year":"2016","unstructured":"Pinkosky\u00a0SL, Newton\u00a0RS, Day\u00a0EA et al (2016) Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL\u2011C and attenuates atherosclerosis. Nat Commun 7:13457","journal-title":"Nat Commun"},{"issue":"6","key":"1524_CR33","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s40256-020-00399-w","volume":"20","author":"S Niman","year":"2020","unstructured":"Niman\u00a0S, Rana\u00a0K, Reid\u00a0J et\u00a0al (2020) A review of the efficacy and tolerability of bempedoic acid in the treatment of hypercholesterolemia. Am J Cardiovasc Drugs 20(6):535\u2013548","journal-title":"Am J Cardiovasc Drugs"},{"issue":"11","key":"1524_CR34","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMoa1806747","volume":"380","author":"BA Ference","year":"2019","unstructured":"Ference\u00a0BA, Ray\u00a0KK, Catapano\u00a0AL et\u00a0al (2019) Mendelian randomization study of ACLY and cardiovascular disease. N\u00a0Engl J Med 380(11):1033\u20131042","journal-title":"N Engl J Med"},{"key":"1524_CR35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2215024","author":"SE Nissen","year":"2023","unstructured":"CLEAR Outcomes Investigators, Nissen\u00a0SE, Lincoff\u00a0AM, Brennan\u00a0D, Ray\u00a0KK et al (2023) Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. N\u00a0Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2215024. Zugegriffen: 10.02.23","journal-title":"N Engl J Med"},{"issue":"15","key":"1524_CR36","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1615758","volume":"376","author":"KK Ray","year":"2017","unstructured":"Ray\u00a0KK, Landmesser\u00a0U, Leiter\u00a0LA et\u00a0al (2017) Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. N\u00a0Engl J Med 376(15):1430\u20131440","journal-title":"N Engl J Med"},{"issue":"12","key":"1524_CR37","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s11886-020-01427-6","volume":"22","author":"D Sinning","year":"2020","unstructured":"Sinning\u00a0D, Landmesser\u00a0U (2020) Low-density lipoprotein-cholesterol lowering strategies for prevention of atherosclerotic cardiovascular disease: focus on siRNA treatment targeting PCSK9 (Inclisiran). Curr Cardiol Rep 22(12):176","journal-title":"Curr Cardiol Rep"},{"key":"1524_CR38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","volume":"382","author":"KK Ray","year":"2020","unstructured":"Ray\u00a0KK, Wright\u00a0RS, Kallend\u00a0D et\u00a0al (2020) Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N\u00a0Engl J Med 382:1507\u20131519","journal-title":"N Engl J Med"},{"issue":"3","key":"1524_CR39","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1056\/NEJMoa1905239","volume":"382","author":"S Tsimikas","year":"2020","unstructured":"Tsimikas\u00a0S, Karwatowska-Prokopczuk\u00a0E, Gouni-Berthold\u00a0I et al (2020) AKCEA-APO(a)-LRx study investigators. Lipoprotein(a) reduction in persons with cardiovascular disease. N\u00a0Engl J Med 382(3):244\u2013255","journal-title":"N Engl J Med"},{"issue":"17","key":"1524_CR40","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","volume":"327","author":"SE Nissen","year":"2022","unstructured":"Nissen\u00a0SE, Wolski\u00a0K, Balog\u00a0C et\u00a0al (2022) Single ascending dose study of a\u00a0short interfering RNA targeting lipoprotein(a) production in individuals with elevated plasma lipoprotein(a) levels. JAMA 327(17):1679\u20131687","journal-title":"JAMA"},{"issue":"1","key":"1524_CR41","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","volume":"28","author":"MJ Koren","year":"2022","unstructured":"Koren\u00a0MJ, Moriarty\u00a0PM, Baum\u00a0SJ et\u00a0al (2022) Preclinical development and phase 1 trial of a\u00a0novel siRNA targeting lipoprotein(a). Nat Med 28(1):96\u2013103","journal-title":"Nat Med"},{"issue":"20","key":"1524_CR42","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","volume":"387","author":"ML O\u2019Donoghue","year":"2022","unstructured":"OCEAN(a)-DOSE Trial Investigators, O\u2019Donoghue\u00a0ML, Rosenson\u00a0RS, Gencer\u00a0B, L\u00f3pez\u00a0JAG et al (2022) Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease. N\u00a0Engl J Med 387(20):1855\u20131864","journal-title":"N Engl J Med"},{"issue":"1","key":"1524_CR43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11883-020-0823-5","volume":"22","author":"S Yamashita","year":"2020","unstructured":"Yamashita\u00a0S, Masuda\u00a0D, Matsuzawa\u00a0Y (2020) Pemafibrate, a\u00a0new selective PPAR\u03b1 modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases. Curr Atheroscler Rep 22(1):5","journal-title":"Curr Atheroscler Rep"},{"issue":"14","key":"1524_CR44","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1093\/eurheartj\/ehab820","volume":"43","author":"JC Tardif","year":"2022","unstructured":"Tardif\u00a0JC, Karwatowska-Prokopczuk\u00a0E, Amour\u00a0ES, Ballantyne\u00a0CM et al (2022) Apolipoprotein C\u2011III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. Eur Heart\u00a0J 43(14):1401\u20131412","journal-title":"Eur Heart J"},{"issue":"3","key":"1524_CR45","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1056\/NEJMoa1701329","volume":"377","author":"MJ Graham","year":"2017","unstructured":"Graham\u00a0MJ, Lee\u00a0RG, Brandt\u00a0TA et\u00a0al (2017) Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. N\u00a0Engl J Med 377(3):222\u2013232","journal-title":"N Engl J Med"},{"issue":"8","key":"1524_CR46","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","volume":"383","author":"FJ Raal","year":"2020","unstructured":"ELIPSE HoFH Investigators, Raal\u00a0FJ, Rosenson\u00a0RS, Reeskamp\u00a0LF et\u00a0al (2020) Evinacumab for homozygous familial hypercholesterolemia. N\u00a0Engl J Med 383(8):711\u2013720","journal-title":"N Engl J Med"},{"issue":"24","key":"1524_CR47","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1056\/NEJMoa2031049","volume":"383","author":"RS Rosenson","year":"2020","unstructured":"Rosenson\u00a0RS, Burgess\u00a0LJ, Ebenbichler\u00a0CF et\u00a0al (2020) Evinacumab in patients with refractory hypercholesterolemia. N\u00a0Engl J Med 383(24):2307\u20132319","journal-title":"N Engl J Med"},{"issue":"9","key":"1524_CR48","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1194\/jlr.RA120000888","volume":"61","author":"RC Adam","year":"2020","unstructured":"Adam\u00a0RC, Mintah\u00a0IJ, Alexa-Braun\u00a0CA et al (2020) Angiopoietin-like protein 3 governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance. J\u00a0Lipid Res 61(9):1271\u20131286","journal-title":"J Lipid Res"},{"issue":"7","key":"1524_CR49","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1194\/jlr.M054882","volume":"56","author":"Y Wang","year":"2015","unstructured":"Wang\u00a0Y, Gusarova\u00a0V, Banfi\u00a0S, Gromada\u00a0J, Cohen\u00a0JC, Hobbs\u00a0HH (2015) Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion. J\u00a0Lipid Res 56(7):1296\u20131307","journal-title":"J Lipid Res"},{"issue":"7859","key":"1524_CR50","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1038\/s41586-021-03534-y","volume":"593","author":"K Musunuru","year":"2021","unstructured":"Musunuru\u00a0K, Chadwick\u00a0AC, Mizoguchi\u00a0T et\u00a0al (2021) In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. Nature 593(7859):429\u2013434","journal-title":"Nature"},{"issue":"39","key":"1524_CR51","doi-asserted-by":"crossref","first-page":"4007","DOI":"10.1093\/eurheartj\/ehab299","volume":"42","author":"A Sahebkar","year":"2021","unstructured":"Sahebkar\u00a0A, Momtazi-Borojeni\u00a0AA, Banach\u00a0M (2021) PCSK9 vaccine: so near, yet so far! Eur Heart\u00a0J 42(39):4007\u20134010","journal-title":"Eur Heart J"},{"key":"1524_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.02.018","author":"CM Ballantyne","year":"2023","unstructured":"Ballantyne\u00a0CM, Banka\u00a0P, Mendez\u00a0G, Garcia\u00a0R et al (2023) Efficacy and safety of the oral PCSK9 inhibitor MK-0616: a\u00a0phase 2b randomized controlled trial. J\u00a0Am Coll Cardiol. https:\/\/doi.org\/10.1016\/j.jacc.2023.02.018. Zugegriffen: 10.02.23","journal-title":"J Am Coll Cardiol"},{"issue":"25","key":"1524_CR53","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1056\/NEJMoa1800389","volume":"378","author":"R Estruch","year":"2018","unstructured":"Estruch\u00a0R, Ros\u00a0E, Salas-Salvad\u00f3\u00a0J, Covas\u00a0MI et al (2018) Primary prevention of cardiovascular disease with a\u00a0Mediterranean diet supplemented with extra-virgin olive oil or nuts. N\u00a0Engl J Med 378(25):e34","journal-title":"N Engl J Med"},{"key":"1524_CR54","unstructured":"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04023552?cond=Pelacarsen&draw=2&rank=3. Zugegriffen: 10.02.23"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-023-01524-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-023-01524-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,23]],"date-time":"2023-08-23T16:02:53Z","timestamp":1692806573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-023-01524-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,6]]},"references-count":54,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["1524"],"URL":"https:\/\/doi.org\/10.1007\/s00108-023-01524-y","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,6]]},"assertion":[{"value":"20 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"G.\u00a0Klose: Unterst\u00fctzung von Fortbildungsveranstaltungen durch Amgen, BMS, Daiichi Sankyo, esanum, Novartis, Sanofi, Sobi, Synlab, Ultragenyx. I.\u00a0Gouni-Berthold: Beratungshonorare von Amarin, Sanofi, Daiichi Sankyo, Akcea, Novartis, Unterst\u00fctzung von Fortbildungsveranstaltungen durch Amgen, Sanofi, Daiichi Sankyo, Novartis, Synlab. W.\u00a0M\u00e4rz: Unterst\u00fctzung von Fortbildungsveranstaltungen\/Kongressen \u00a0 Aegerion, Akcea, Amarin, Amgen, Amryt, Sanofi, Daiichi Sankyo, Novartis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}